Objective(s): Coronary artery disease (CAD) which may lead to myocardial infarction (MI) is a complex one. Great effort has been devoted to identification of genes that increase susceptibility to CAD or provide protection. A 21-bp deletion in the MEF2A gene, which encodes a member of the myocyte enhancer factor 2 family of transcription factors, has been reported in patients of a single pedigree that exhibited autosomal-dominant inheritance of CAD. Subsequent analysis of genetic variants within the gene in CAD and MI case-control settings produced inconsistent results. Here, we aimed at assessing the contribution of MEF2A to CAD in a cohort of Iranian CAD patients. Materials and Methods: Exon 11 of MEF2A wherein the above mentioned 21-bp deletion and a polyglutamine (CAG)n polymorphism are positioned was sequenced by the dideoxy-nucleotide termination protocol. In 52 CAD patients from 12 families (3-7 affected members per family) and 76 Iranian control individuals. All exons of the gene were sequenced in 10 patients and 10 controls. Results: The 21-bp deletion was observed neither among the patients nor the control individuals. Four alleles of the polyglutamine (CAG)n polymorphism were found, but there were no significant differences in allelic frequencies between patients and controls. Sequencing of all exons of MEF2A revealed the presence of 12 novel sequence variations in introns and flanking regions of MEF2A gene, not associated with disease status.
Introduction
The evidence for heritability of coronary artery disease (CAD) is striking, with a positive family history being one of the most important risk factors for this complex trait (1) . In recent years, there has been some progress in the identification of genes that are associated with susceptibility to the development of CAD. But, there has also been remarkable lack of replication among studies and difficulty in identifying genes with impressive linkage peaks (2) .
Myocyte enhancer factor 2 (MEF2) constitutes a family of transcription factors composed of four members: MEF2A, MEF2B, MEF2C, and MEF2D. The MEF2 transcription factors bind to their cognate DNA sequence CAT(A/T)4TAG/A in the regulatory regions of several genes. The promoter regions of various genes expressed in the heart contain MEF2 binding sequences, and MEF2 could regulate inducible expression of some of these genes in muscle and endothelium of coronary arteries, among other cell types (3) . The MEF2A gene, located at chromosome position 15q26.3, is composed of 11 exons spread over ~115 kb (Figure 1) , and is expressed at high levels in skeletal, cardiac, smooth muscle, neuronal cells, and in the endothelium of coronary arteries (4, 5) .
A deletion mutation in MEF2A was identified in a large pedigree with an autosomal dominant inheritance pattern of myocardial infarction (MI) and CAD (4). The MEF2A 21-bp deletion in exon 11 co-segregated with the presence or absence of CAD or MI in the family, and was not found in hundreds of controls without documented CAD by angiography (4). Furthermore, this deletion correlated with lack of nuclear translocation and a marked reduction of transcription activity. However, lack of replication has led to controversies regarding the role of MEF2A with respect to CAD (3, 6, 7 with coronary disease, and one of these point mutations, Pro297Leu, was independently replicated (3, 8) . Although initial studies supported the involvement of MEF2A variants in the occurence of CAD/MI, these variants were later identified in healthy individuals, thus raising the possibility that they were rare DNA polymorphisms not directly related to the risk for CAD (6) .
The role of MEF2A in the pathogenesis of cardiovascular diseases still remains uncertain. In fact, several case-control studies have been undertaken, but controversial results were found (3, 6, (9) (10) (11) (12) . A large study by Lieb et al on more than 1700 patients with MI, 2 large control populations, and extended families with apparently Mendelian inheritance of the disease showed no evidence of an association between MEF2A and MI (13).
Additionally, a meta-analysis provided no convincing evidence for the genetic involvement of MEF2A gene (CAG)n polymorphism in CAD (14) . The (CAG)n tract encodes polyglutamine tandem repeats ((Q)n)in the protein product of the gene. Here, we report results of screening the exon 11 21-bp deletion mutations and the CAG repeat polymorphism within the same exon of the MEF2A gene in 12 Iranian CAD pedigrees to assess whether an association exists between the MEF2A genetic variants and CAD in these pedigrees.
Materials and Methods

Ethics statement
This research was performed in accordance with the Declaration of Helsinki and with approval of the ethics board of the University of Tehran. Participants or their guardians consented to participate after being informed of the nature of the research.
Study population
The study population comprised 12 families with 52 CAD patients and 76 healthy unrelated Iranian controls aged over 60 years. Coronary angiography revealed >50% stenosis in at least 1 major coronary artery in all the patients with CAD. Risk factors for CAD, such as hypertension, diabetes mellitus, hypercholesterolemia, and smoking were evaluated on the basis of the medical history, current medications, or the findings of examination during hospitalization. Obesity was defined as a body mass index (BMI) of 27 kg/m 2 or more. The clinical features of the affected individuals were recorded. Controls were selected from Iranian peoples without any cardiovascular disease (41 women, 35 men; mean age = 56 years, SD = 10).
Sequencing of MEF2A
Blood samples (5 ml) were drawn and genomic DNA was extracted from peripheral blood leukocytes by standard phenol-chloroform extraction.
Exon 11 of MEF2A was screened for mutations by direct sequencing in all 52 patients and 76 controls. The Sanger di-deoxy nucleotide termination protocol was used for sequencing. Exon 11 of MEF2A and its flanking intronic sequences in all the patients and controls were amplified by the polymerase chain reaction (PCR) and subsequently sequenced (Big Dye kit and the Prism 3700 sequencer; Applied Biosystems, Foster City, CA, USA). Primers used for PCR amplification and sequencing were designed by the Primer 3 software (http://frodo.wi.mit.edu/cgi bin/primer3/primer3) according to reference sequence (NM_005920.2) ( Table 1 ). Sequences were analyzed through their comparison with the reference sequence (NT_037852.6) using Sequencher 4.8 software (Gene Codes, Ann Arbor, MI, USA).
Finally, all exons of the MEF2A gene, including those that encode the 5´ and 3´untranslated regions, and flanking intronic boundaries were sequenced in two representative CAD patients from each of five extended families (n=10) and in 10 controls. The sequencing of all the exons was done using a Next Generation Sequencing protocol at Illumina (Illumina, San Diego, CA, USA).
Statistical analysis
The clinical characteristics of the continuous variables were expressed as mean ± SD, and were tested using 2-sample t-test. Allele frequencies in patients and controls were compared using χ 2 test. All statistical analyses were done using SPSS statistical package (v.11.0).
Results
Clinical data
Clinical data on classical CAD risk factors such as hypertension, hypercholesterolemia, diabetes mellitus, obesity, and smoking are presented in Table  2 . The occurrence of all risk factors was higher among the patient cohort as compared to controls.
Genotyping of the 21-bp deletion, assessment of number of CAG repeats, and MEF2A sequence variations None of the 52 CAD affected individuals and none of the 76 control individuals carried the 21-bp deletion mutation. The allele distribution of the (CAG)n polymorphism is shown in Table 3 . The number of the CAG triplet repeats ranged from 9 to12 among both patients and controls. The frequencies of the alleles were similar in the patient and control groups, and the two groups showed no statistically significant difference in this regard (P=0.12). The majority of patients and the majority of controls had 9 or 11 repeats.
Results of sequencing all exons of MEF2A by next generation sequencing in ten patients and ten controls, confirmed absence of the 21-bp deletion in these individuals. However, 31 sequence variations were found in MEF2A in the DNAs of the 20 individuals sequenced; 5 of these were found only in patients, 2 were found only in controls, and 24 were found in both groups (Table 4) . Nineteen of the variations had been previously reported as polymorphisms, and 12 are novel variations. None of the novel variations were positioned within amino acid coding regions, and none were predicted to affect splicing. Five of the previously reported variations were within codons, and four of these affected synonymous changes (p.G443G, p.Q291Q, p.N289N and p.P472P). The only variation that caused an amino acid change (p.P421QQP) was observed in both patients and controls. None of the sequence variations within MEF2A were associated with CAD status. gene in 753 patients and 1644 controls excluded their role in susceptibility for MI. However, an evaluation of the frequency of the 21-bp deletion in sporadic patients was lacking in this study (13) .
Here, we screened 21-bp deletion in a total of 52 patients with CAD from 12 families and 75 healthy controls and sequenced all exons of the MEF2A gene in 10 CAD patients and 10 controls. We did not find the 21-bp deletion in any patient or control individual and did not observe a correlation between the CAG repeat number and disease status. Furthermore, we did not detect a correlation between disease status and any of the 31 variations found among the patient and control individuals of whom the gene was sequenced. Most of the variations were intronic or in regions that do not code amino acids. Taken together, our analyses indicate a lack of evidence for a significant association between CAD and MEF2A in the Iranian patients studied.
Conclusion
Our analyses do not support the role of MEF2A in CAD, at least among the Iranian patients studied. The gene is unlikely to contribute to disease status in a notable fraction of Iranian CAD patients.
